v3.26.1
Consolidated Balance Sheets - USD ($)
Dec. 31, 2025
Dec. 31, 2024
Current assets:    
Cash and cash equivalents $ 4,310,354 $ 3,502,077
Unbilled receivable 420,345 124,115
Prepaid expenses and other current assets 2,511,769 1,718,490
Total current assets 7,242,468 5,344,682
Property and equipment, net 124,129
Other assets 85,882 252,550
Total assets 7,452,479 5,597,232
Current liabilities:    
Accounts payable 3,267,610 1,357,079
Accrued expenses and other liabilities 993,411 548,458
Notes payable and accrued interest 306,708 301,660
Total current liabilities 4,567,729 2,207,197
Long-term liabilities:    
Other long-term liabilities 10,096
Total long-term liabilities 10,096
Total liabilities 4,567,729 2,217,293
Commitments and contingencies (Note 7)  
Stockholders’ equity    
Preferred stock, $0.0001 par value, 1,500,000 shares authorized, 4,000 shares issued, 3,305 shares outstanding, and $3,635,500 liquidation preference at December 31, 2025; no shares issued and outstanding at December 31, 2024
Common stock, $0.0001 par value, 250,000,000 shares authorized at December 31, 2025 and December 31, 2024; 4,574,983 and 1,355,779 shares issued at December 31, 2025 and December 31, 2024, respectively; 4,574,977 and 1,355,773 shares outstanding at December 31, 2025 and December 31, 2024, respectively 459 136
Additional paid-in capital 142,933,260 133,252,585
Accumulated deficit (139,719,999) (129,544,299)
Total Ensysce Biosciences, Inc. stockholders’ equity 3,213,720 3,708,422
Noncontrolling interests in stockholders’ deficit (328,970) (328,483)
Total stockholders’ equity 2,884,750 3,379,939
Total liabilities and stockholders’ equity $ 7,452,479 $ 5,597,232

Source